A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: A randomized, placebo-controlled, double-blind, multicenter 52-week phase 2 trial of resveratrol in individuals with mild to moderate Alzheimer disease (AD) examined its safety and tolerability and effects on biomarker (plasma Aβ40 and Aβ42, CSF Aβ40, Aβ42, tau, and phospho-tau 181) and volumetric MRI outcomes (primary outcomes) and clinical outcomes (secondary outcomes).
Methods: Participants (n = 119) were randomized to placebo or resveratrol 500 mg orally once daily (with dose escalation by 500-mg increments every 13 weeks, ending with 1,000 mg twice daily). Brain MRI and CSF collection were performed at baseline and after completion of treatment. Detailed pharmacokinetics were performed on a subset (n = 15) at baseline and weeks 13, 26, 39, and 52.
Results: Resveratrol and its major metabolites were measurable in plasma and CSF. The most common adverse events were nausea, diarrhea, and weight loss. CSF Aβ40 and plasma Aβ40 levels declined more in the placebo group than the resveratrol-treated group, resulting in a significant difference at week 52. Brain volume loss was increased by resveratrol treatment compared to placebo.
Conclusions: Resveratrol was safe and well-tolerated. Resveratrol and its major metabolites penetrated the blood–brain barrier to have CNS effects. Further studies are required to interpret the biomarker changes associated with resveratrol treatment.
Classification of evidence: This study provides Class II evidence that for patients with AD resveratrol is safe, well-tolerated, and alters some AD biomarker trajectories. The study is rated Class II because more than 2 primary outcomes were designated.
GLOSSARY
- 3G-RES=
- 3-O-glucuronidated-resveratrol;
- 4G-RES=
- 4-O-glucuronidated-resveratrol;
- AD=
- Alzheimer disease;
- ADAS-cog=
- Alzheimer's Disease Assessment Scale–cognitive;
- ADCS=
- Alzheimer's Disease Cooperative Study;
- ADCS-ADL=
- Alzheimer's Disease Cooperative Study Activities of Daily Living Scale;
- AE=
- adverse event;
- BMI=
- body mass index;
- CDR-SOB=
- Clinical Dementia Rating-sum of boxes;
- Cmax=
- maximal plasma concentration;
- DMSO=
- dimethyl sulfoxide;
- ITT=
- intention-to-treat;
- MMRM=
- mixed-model repeated-measures;
- MMSE=
- Mini-Mental State Examination;
- NPI=
- Neuropsychiatric Inventory;
- S-RES=
- 3-sulfated-resveratrol;
- SAE=
- serious adverse event
Footnotes
Coinvestigators are listed on the Neurology® Web site at Neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by NIH.
Supplemental data at Neurology.org
- Received January 6, 2015.
- Accepted in final form June 19, 2015.
- © 2015 American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Plasma Aβ40 and Aβ42 and Alzheimer’s diseaseRelation to age, mortality, and riskR. Mayeux, L. S. Honig, M.-X. Tang et al.Neurology, November 10, 2003 -
Articles
Biochemical markers in persons with preclinical familial Alzheimer diseaseJ. M. Ringman, S. G. Younkin, D. Pratico et al.Neurology, May 28, 2008 -
Articles
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer diseaseN. C. Fox, R. S. Black, S. Gilman et al.Neurology, April 07, 2005 -
Articles
Change in plasma Aβ peptides and onset of dementia in adults with Down syndromeN. Schupf, W.B. Zigman, M.-X. Tang et al.Neurology, November 01, 2010